

Certificate of Mailing

Date of Deposit October 18, 2001

Label Number: EL874187256US

I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to: BOX PATENT APPLICATION, Commissioner for Patents, Washington, D.C. 20231.

Guy Beardsley

Printed Name of Person Mailing Correspondence

  
Signature of Person Mailing Correspondence

APPLICATION

FOR

UNITED STATES LETTERS PATENT

APPLICANT : FREDERICK M. AUSUBEL, RHONDA FEINBAUM,  
MAN WAH TAN, GENVIÈVE ALLOING, AND DENNIS KIM

TITLE : METHODS FOR SCREENING AND IDENTIFYING  
HOST PATHOGEN DEFENSE GENES

10042066-101801

METHODS FOR SCREENING AND IDENTIFYING  
HOST PATHOGEN DEFENSE GENES

Statement as to Federally Sponsored Research

This invention was made, in part, with government funding. The Government therefore has certain rights in the invention.

Background of the Invention

This application is a continuation-in-part of U.S. Serial No. 09/827,789 filed on April 6, 2001 which, in turn, claims benefit of U.S. provisional application 60/195,097, filed on April 6, 2000.

The invention relates to screening methods for identifying host pathogen defense genes and their regulating pathways, and for identifying drugs that enhance or stimulate the resistance of a host to pathogen infection or that block pathogen virulence.

Microbial pathogens use a variety of complex strategies to subvert host cellular functions to ensure their multiplication and survival. Some pathogens that have co-evolved or have had a long-standing association with their hosts utilize finely tuned host-specific strategies to establish a pathogenic relationship. During infection, pathogens encounter different conditions, and respond by expressing virulence factors that are appropriate for the particular environment, host, or both.

Although antibiotics have been effective tools in treating infectious disease, the emergence of drug resistant pathogens is becoming problematic in the clinical setting. New antibiotics or antipathogenic molecules are therefore needed to combat such drug resistant pathogens. Similarly, the discovery of drugs that maximize host pathogen defense responses is also warranted. Moreover, a need in the art exists for screening methods aimed at identifying and characterizing the host defense response, including the genes regulating the pathogen defense pathway that enable hosts to combat infecting pathogens.

Summary of the Invention

In one aspect, the invention features a method for identifying a nematode having enhanced susceptibility to a pathogen. The method, in general, involves the steps of:

(a) exposing a mutagenized nematode to a pathogen; and (b) determining survival of the mutagenized nematode when exposed to the pathogen, decreased survival of the mutagenized nematode relative to a non-mutagenized nematode identifying the mutagenized nematode as one having enhanced susceptibility to the pathogen. In preferred embodiments, the mutagenized nematode is *C. elegans* (such as an N2 L4 worm). In other preferred embodiments, the pathogen is a bacterium (such as *Pseudomonas aeruginosa* (strain PA14) or *Enterococcus faecalis*). In still other preferred embodiments, the mutagenized nematode is exposed to the pathogen under slow killing conditions. In yet another embodiment, the mutagenized nematode includes a mutation in a component of a MAPK signal transduction pathway (such as mutations in *esp-2*, *esp-8*, and *pmk-1*).

In another aspect, the invention features a method for identifying a pathogen defense response gene. The method, in general, involves the steps of: (a) exposing a mutagenized nematode to a pathogen; (b) determining survival of the mutagenized nematode when exposed to the pathogen, decreased survival of the mutagenized nematode relative to a non-mutagenized nematode indicating a mutation in a nematode pathogen defense response gene; and (c) using the mutation as a marker for identifying the pathogen defense response gene.

In another aspect, the invention features a method for identifying a nematode having enhanced susceptibility to a pathogen. The method, in general, involves the steps of: (a) providing a nematode including a double-stranded RNA (dsRNA), wherein the dsRNA silences the expression of an endogenous nematode gene; (b) exposing the nematode to a pathogen; and (c) determining survival of the nematode when exposed to the pathogen, decreased survival of the nematode having dsRNA relative to a control nematode identifying the nematode having dsRNA as one with enhanced susceptibility to the pathogen. In preferred embodiments, the nematode is *C. elegans* (e.g., an N2 L4 worm) and the dsRNA is microinjected into the nematode. In another embodiment, the nematode including the dsRNA results from the nematode ingesting dsRNA-expressing bacteria.

In other preferred embodiments, the pathogen is a bacterium (e.g., *Pseudomonas aeruginosa* (strain PA14) or *Enterococcus faecalis*). Preferably, the nematode is exposed to the pathogen under slow killing conditions.

In yet another aspect, the invention features a method for identifying a pathogen defense response gene. The method, in general, includes the steps of: (a) providing a nematode including a dsRNA, wherein the dsRNA silences an endogenous nematode gene; (b) exposing the nematode to a pathogen; (c) determining survival of the

10042066-101801

nematode when exposed to the pathogen, wherein decreased survival of the nematode having dsRNA relative to a control nematode indicates that the dsRNA silences a pathogen defense gene; and (d) determining the nucleic acid sequence of the dsRNA, thereby identifying the pathogen defense response gene. In preferred embodiments, the nucleic acid sequence of the dsRNA is known. In other preferred embodiments, the nematode is *C. elegans* (e.g., an N2 L4 worm). And in still other preferred embodiments, the dsRNA is microinjected into the nematode or results from a nematode ingesting dsRNA-expressing bacteria.

In other preferred embodiments, the pathogen is a bacterium (e.g., *Pseudomonas aeruginosa* (strain PA14) or *Enterococcus faecalis*). Preferably, the nematode is exposed to the pathogen under slow killing conditions. In yet another embodiment, the mutagenized nematode includes a mutation in a component of a MAPK signal transduction pathway (such as mutations in *esp-2*, *esp-8*, and *pmk-1*).

In yet another aspect, the invention features a method for identifying a component of a MAPK signal transduction pathway conferring innate immunity to a nematode. The method, in general, involves the steps of: (a) providing a nematode having a mutation in a component of a MAPK signal transduction pathway and a pathogen; and (b) determining survival of the nematode when exposed to the pathogen, decreased survival of the nematode relative to a wild type nematode identifying a component of the MAPK signal transduction pathway that confers innate immunity to a nematode. In preferred embodiments, the component of the MAPK signal transduction pathway is a gene encoding a MAPK (e.g., *pmk-1*), a gene encoding a MAPKK (e.g., *esp-2*); or a gene encoding a MAPKKK (e.g., *esp-8*).

In another aspect, the invention features a method for identifying a nematode having enhanced susceptibility to a pathogen, involving the steps of: (a) providing a nematode including a double-stranded RNA (dsRNA), wherein the dsRNA silences the expression of a component of a MAPK signal transduction pathway; (b) exposing the nematode to a pathogen; and (c) determining survival of the nematode when exposed to the pathogen, decreased survival of the nematode having dsRNA relative to a control nematode identifying the nematode having dsRNA as one with enhanced susceptibility to the pathogen. In preferred embodiments, the component of the MAPK signal transduction pathway is a gene encoding a MAPK; a gene encoding a MAPKK; or a gene encoding a MAPKKK.

In still another aspect, the invention features a method for identifying a compound that enhances a defense response to a pathogen. The method, in general, involves the steps of: (a) exposing a nematode, having enhanced pathogen susceptibility, to a test

compound and a pathogen; and (b) determining survival of the nematode exposed to the pathogen, increased survival of the nematode relative to the survival of the nematode in the absence of the test compound identifying a compound that enhances a defense response to a pathogen.

5 In preferred embodiments, the nematode utilized in the compound screening assays is a mutagenized nematode identified according to the above-described method. In other preferred embodiments, the nematode includes dsRNA. Preferably, the test compound is provided in a compound library; is a small organic compound; or is a peptide, peptidomimetic, or an antibody or fragment thereof. In yet another embodiment,  
10 the mutagenized nematode includes a mutation in a component of a MAPK signal transduction pathway (such as mutations in *esp-2*, *esp-8*, and *pmk-1*).

In still other aspects, the invention features a method for identifying a compound that enhances a defense response to a pathogen, the method involving the steps of: (a) exposing a nematode, having a mutated MAPK signaling pathway, to a test compound  
15 and a pathogen; and (b) determining survival of the nematode exposed to the pathogen, increased survival of the nematode relative to the survival of the nematode in the absence of the test compound identifying a compound that enhances a defense response to a pathogen. In preferred embodiments, the component of the MAPK signal transduction pathway is a gene encoding a MAPK; a gene encoding a MAPKK, or a gene encoding a  
20 MAPKKK.

Exemplary pathogenic bacteria useful in the methods of the invention include, without limitation, *Aerobacter*, *Aeromonas*, *Acinetobacter*, *Agrobacterium*, *Bacillus*, *Bacteroides*, *Bartonella*, *Bordetella*, *Bordetella*, *Borrelia*, *Brucella*, *Burkholderia*, *Calymmatobacterium*, *Campylobacter*, *Citrobacter*, *Clostridium*, *Corynebacterium*,  
25 *Enterobacter*, *Enterococcus*, *Escherichia*, *Francisella*, *Gardnerella*, *Haemophilus*, *Hafnia*, *Helicobacter*, *Klebsiella*, *Legionella*, *Listeria*, *Morganella*, *Moraxella*, *Mycobacterium*, *Neisseria*, *Pasteurella*, *Proteus*, *Providencia*, *Pseudomonas*, *Salmonella*, *Serratia*, *Shigella*, *Staphylococcus*, *Streptococcus*, *Stentorophomonas*, *Treponema*, *Xanthomonas*, *Vibrio*, and *Yersinia*.

30 By "enhanced susceptibility to a pathogen" is meant that the genome of a host organism has been altered (e.g., by introducing a dsRNA molecule that silences an endogenous gene of a nematode) or mutated to render the host as having greater sensitivity to a pathogen than its unaltered or non-mutated counterpart. Typically, host organisms having enhanced susceptibility to a pathogen are preferably at least 5%, more  
35 preferably at least 25%, and most preferably at least 50% or more sensitive to the effects of a pathogen, when compared to a non-altered or non-mutated host organism.

By “inhibits a pathogen” is meant the ability of a test compound to decrease, suppress, attenuate, diminish, arrest, or stabilize the development or progression of a pathogen-mediated disease or infection in a eukaryotic host organism. Preferably, such inhibition decreases pathogenicity by at least 5%, more preferably by at least 25%, and most preferably by at least 50% or more, as compared to symptoms in the absence of the test compound in any appropriate pathogenicity assay (for example, those assays described herein). In one particular example, inhibition may be measured by monitoring pathogenic symptoms in a nematode infected with a pathogen exposed to a test compound or extract, a decrease in the level of pathogenic symptoms relative to the level of symptoms in the host organism not exposed to the compound indicating compound-mediated inhibition of the pathogen.

By “detectable marker” is meant a gene whose expression may be assayed; such genes include, without limitation,  $\beta$ -glucuronidase (GUS), luciferase (LUC), chloramphenicol transacetylase (CAT), green fluorescent protein (GFP), and  $\beta$ -galactosidase.

By “a component of a MAPK signaling pathway” is meant a polypeptide with identity to the mitogen-activated protein kinases (MAPK) or an polypeptide with identity to a MAPKK or MAPKKK. The core of a MAPK signaling pathway is composed of a MAP kinase (MAPK) (such as p38, JNKs, Jun amino-terminal kinases, or ERKs, extracellular signal-related kinases) whose activity is regulated via a MAPK-activating MAPK kinase (MAPKK) (such as MKK3/6, MKK4/7, or MEK1/2), which in turn is activated by a MAPKK-activating MAPKK kinase (MAPKKK) (such as ASK1 or c-Raf).

By “a mutated MAPK signaling pathway” is meant a MAPK signaling pathway having an alteration that enhances or diminishes a nematode innate immune response. Such an alteration might include without limitation the genetic inhibition of a MAPK (or a MAPKK or MAPKKK) by chemical or transposon-mediated mutagenesis, interference with MAPK gene expression by RNA-mediated interference, or the expression of a MAPK transgene, such a transgene might overexpress or interfere with a MAPK signaling component.

By “innate immunity” is meant a native or natural immunity whose defense mechanisms are present prior to exposure to infectious microbes or foreign substances.

The present invention provides a number of advantages. For example, the invention facilitates the identification of novel targets and therapeutic approaches for preparing therapeutic agents active on host factors and genes that enable a host to mount its defense against pathogen invasion and infection.

10042066-101301

The invention also provides long awaited advantages over a wide variety of standard screening methods used for distinguishing and evaluating the efficacy of a compound against virtually any number of pathogens. In one particular example, the screening methods described herein allow for the simultaneous evaluation of host toxicity as well as anti-pathogenic potency in a simple *in vivo* screen. Moreover, the methods of the invention allow one to evaluate the ability of a compound to inhibit pathogenesis, and, at the same time, to evaluate the ability of the compound to stimulate and strengthen a host's response to pathogenic attack.

Accordingly, the methods of the invention provide a straightforward means to identify compounds that are both safe for use in eukaryotic host organisms (i.e., compounds which do not adversely affect the normal development and physiology of the organism) and efficacious against pathogenic microbes that establish infection and disease in their hosts. In addition, the methods of the invention provide a route for analyzing virtually any number of compounds for anti-pathogenic effect or for activating host defense pathways with high-volume throughput, high sensitivity, and low complexity. The methods are also relatively inexpensive to perform and enable the analysis of small quantities of active substances found in either purified or crude extract form. Furthermore, the methods disclosed herein provide a means for identifying compounds that have the capability of crossing eukaryotic cell membranes and which maintain therapeutic efficacy in an *in vivo* method of administration. In addition, the above-described methods of screening are suitable for both known and unknown compounds and compound libraries.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.

### Detailed Description of the Invention

The drawings will first be described.

#### Drawings

Fig. 1 shows a graph of several *C. elegans* mutants having enhanced susceptibility to PA14.

Fig. 2 is a graph showing a comparison of the susceptibility of *esp-1* and N2 young adults under SKA conditions.

Fig. 3 is a graph showing a comparison of the susceptibility of various Eat mutants and N2 under SKA (slow killing assay) conditions.

Fig. 4 is a graph showing a comparison of the susceptibility of *esp-2* and N2 under SKA conditions.

Below we describe experimental screens for identifying nematodes having enhanced resistance or susceptibility to the effects of pathogen invasion and infection. The screens and the nematodes described herein therefore provide a useful system for identifying novel host factors and genes responsible for a host's ability to combat infection, as well as for identifying compounds that either inhibit pathogenicity, promote a host's resistance to the pathogen, or both. The following experimental examples are intended to illustrate, not limit, the scope of the claimed invention.

#### Screen for *C. elegans* Mutants that are Resistant to Toxin-Mediated Killing by PA14

*C. elegans* fast-killing and slow-killing assays, respectively described in Mahajan-Miklos et al. (*Cell* 96:47-56, 1999) and Tan et al. (*Proc. Natl. Acad. Sci.* 96: L715-720, 1999), were used in genetic screens to identify host pathogen defense genes that are involved in the response to either toxin- or infection-mediated killing. Because the worms die rapidly and prior to producing progeny in the fast killing assay (FKA), it is an excellent assay for identifying mutants that are more resistant to toxin-mediated killing. A total of 10,000 ethylmethane sulfonate (EMS) mutagenized haploid genomes were screened for mutants that remained alive after 10 hours of exposure to *Pseudomonas aeruginosa* PA14 under fast killing conditions. Six mutants having resistance against *Pseudomonas* fast killing (designated rap mutants) were identified.

#### Screen for *C. elegans* Mutants with Enhanced Susceptibility to PA14

*C. elegans* mutants having enhanced susceptibility to pathogens (Esp) specifically PA14 under slow killing assay (SKA) conditions were identified using a standard F2 screen. The F2 screen was performed to identify recessive loss-of-function mutations in genes required for the *C. elegans* pathogen defense response. We recovered mutants that were more susceptible to PA14 because the infected worms die as gravid adults. After exposure to PA14, a dead worm containing its brood was transferred to plates seeded with *E. coli*, and its progeny were recovered.

N2 L4 worms were mutagenized with EMS according to standard procedures (Epstein and Shakes, eds., *Methods in Cell Biology, Vol 48, Caenorhabditis elegans: Modern Biological Analysis of an Organism*, Academic Press, 1995) and staged F2 progeny were then exposed to PA14 under SKA conditions. The plates were incubated overnight at 25 °C, and 16-30 hours later screened for dead animals. Animals were determined to be dead when they no longer responded to touch by an eyelash. In control experiments, wild type N2 L4 worms began to die at 42 hours on PA14. Dead worms,



many of which were bags containing hatched larvae, were then transferred to *E. coli* plates to recover their progeny.

In two separate screens, a total of approximately 56,000 haploid genomes were examined for enhanced susceptibility to PA14. In one screen, from 42,000 mutagenized haploid genomes, 224 putative ESP mutants were identified. 132 worms produced no progeny, but of the remaining 92 mutants, 7 candidate Esp mutants were identified after two rounds of re-screening on PA14. Growth of the mutants was compared on PA14 and *E. coli* to establish that the apparent enhanced susceptibility to PA14 was not simply due to a shortened lifespan of the mutants. Figure 1 shows the Esp phenotype of the mutants as isolated from the screen prior to backcrossing. All of the mutants showed some mortality after exposure to PA14 for only 24 hours (0% of N2 are dead at this time, the mutants range from 12-95% dead).

#### Characterization of *C. elegans* Esp Mutants

Genetic and phenotypic characterization of 8 putative Esp mutants was performed as follows. Seven of the eight mutants were backcrossed to N2 at least once. Standard backcrossing was performed by mating N2 males with each Esp mutant. Because it was not possible to distinguish self from cross progeny, matings were transferred daily and F1 hermaphrodites were selected only from mating plates with approximately 50% male progeny. F2 progeny of single F1's were then tested under SKA conditions for sensitivity to PA14. F2 worms that died 24-27 hours after exposure to PA14 were placed onto *E. coli* plates; and their F3 broods were subsequently tested for sensitivity to PA14. Only F2 animals yielding 100% susceptible progeny and that were derived from an F1 animal producing both wild type and susceptible progeny (ideally 1/4 susceptible progeny) were utilized as backcrossed strains.

While backcrossing the mutants to N2, F1 progeny were examined to determine whether the Esp mutations were recessive or X-linked or both. F1 hermaphrodite cross progeny (selected as described above) were tested directly under SKA conditions for sensitivity to PA14. At least 20 hermaphrodites were examined for each mutant tested. In all cases, the selected *esp*/+ F1 hermaphrodites did not have an enhanced susceptibility to PA14, indicating that the Esp mutants were most likely recessive.

To determine whether the Esp mutation was X linked, F1 male progeny from the backcrosses were also examined. Since all male progeny must contain only the X chromosome from the maternal parent (in this case the Esp mutant), X linkage is indicated if the F1 males show the Esp phenotype. Of the seven Esp mutants tested, three

appear to be X linked (X linkage has been confirmed by mapping in the case of *esp-1* and *esp-2* but not for *esp-3*). Table 1 summarizes the characterization of several Esp mutants.

**Table 1: Characterization of Esp Mutants**

Mutant	Gross Phenotype	Backcross	Recessive	Chromosomal location
<i>esp-1</i>	Eat (thin, clear, reduced brood size)	4X	Yes	X (-1.33 to 2.12)
<i>esp-2</i> 8-35-2	Egl	3X	Yes	X (-1.6 to -1.3)
<i>esp-3</i> 6-15		2X	Yes	
<i>esp-4</i> 6-14		ND	ND	
<i>esp-5</i> 6-21		1X	Yes	
<i>esp-6</i> 2-33	Eat (thin)	2	Yes	
<i>esp-7</i> 7-9	Eat (thin), Unc	1X	Yes	
<i>esp-8</i> 8-17	Egl	2X	Yes	II -4.0 to -0.5

#### Characterization of *esp-1*

The mutant designated *esp-1* was characterized according to standard methods. *esp-1* young adults, under SKA conditions, were found to be significantly more susceptible to PA14 than wild type N2 worms (Figure 2). In addition, *esp-1* worms were found to be more sensitive to the bacterium *Enterococcus faecalis*. *esp-1* worms also have an appearance associated with feeding defective mutants; they are thin, have a reduced brood size, and generally look partially starved (Avery, *Genetics* 133:897-917, 1993).

#### Mapping of *esp-1*

The *esp-1* mutation was mapped to a 3.4 map unit interval on chromosome X by STS (sequence tags sites) mapping using the RW700 mapping strain (Williams, *Genetics* 131:609-624 1992). RW700 is a strain of *C. elegans* that carries approximately 500 copies of the transposon TC1 scattered throughout the genome (the standard Bristol strain N2 has comparatively few TC1's). A set of TC1 insertions on each chromosome have been developed as STS markers and can be used to rapidly map a mutation to a genetic

10042066-101801

interval (Williams et al., *Genetics* 131: 609-624, 1992). Each STS marker can be detected by a unique PCR reaction; the presence of the STS marker indicates the RW7000 chromosome and the absence of the STS marker indicates that the sample is homozygous for the N2 chromosome. *esp-1* males were crossed to RW700, and confirmed that the F2 were cross progeny as outlined above for backcrossing with N2.

To identify homozygous *esp-1/esp-1* F2 animals from the RW7000 cross, F3 progeny from individual F2 animals were tested for their sensitivity to PA14. Only F2 animals producing 100% Esp F3 animals were selected as *esp-1/esp-1* homozygotes suitable for mapping analysis. DNA for the PCR analysis was made from starved plates homozygous for the *esp-1* mutation according to standard methods. In this manner, DNA from 150 F2 cross progeny homozygous for the *esp-1* mutation were examined. STS mapping places *esp-1* on chromosome X between markers *stp33* and *stp129* located at -1.33 and +2.12, respectively.

Using the available *C. elegans* genetic map and sequence data, the *esp-1* interval was examined for genes known to mutate to an Esp or a feeding defective phenotype. Two such genes *aex-2* and *eat-13* are located in this interval (Thomas et al., *Genetics* 124: 855-872, 1990; Avery, *Genetics* 133: 897-917, 1993). A mutation in *aex-2*, which causes the worms to become constipated, has also been shown to confer an Esp phenotype. The sensitivity of *aex-2* (and other mutants defective in the expulsion step of defecation) to PA14 is presumably the result of their inability to expel PA14 accumulating in their guts. *esp-1* does not have an obvious defecation phenotype and complements *aex-2* for the Esp phenotype. *eat-13* also maps within the genetic interval defined for *esp-1*. Like *esp-1*, *eat-13* worms are thin and pale, however *eat-13* is less sensitive to PA14 than *esp-1* (see below Figure 3) and *eat-13* complements *esp-1* for both the Eat and Esp phenotypes.

*esp-1* Phenotype is Correlated with a Grinder Abnormality

Since all of the characterized feeding defective mutants have abnormalities in either pharyngeal structure or the motion of the pharynx, the pharyngeal pumping of *esp-1* was examined under Nomarski optics. The nematode feeding cycle has a number of well defined steps (muscle contractions and relaxations) that are required to ingest bacteria, move the bacteria through the pharynx, grind the bacteria, and expel any liquid taken up with the bacteria (Avery, *Genetics* 133: 897-917, 1993).

In *esp-1*, the movement of the grinder is abnormal; grinder function is necessary for breaking up bacteria before they enter the intestine. This observation suggested that the *esp-1* mutant was more susceptible to PA14 because of an increased entry of live

10042066 " 101301  
bacteria into the gut. To test this hypothesis, the susceptibility of various eating defective mutants to PA14 was tested. The slow pumping mutant (*eat-2*) and mutants either strongly (*phm-2*) or slightly (*eat-13*, *eat-14*) defective in the grinder motion were compared with *esp-1*. Only mutants with grinding defects exhibited an enhanced susceptibility to PA14, with the degree of sensitivity correlating with the severity of the grinding defect (Figure 3). In agreement with these results, the *eat-1* mutant which pumps slowly but has a normal grinder function, is not sensitive to PA14 under slow killing conditions.

#### 10 Bacteria are Able to Colonize Rapidly the *esp-1* Gut

To determine whether the grinder defect in *esp-1* results in an abnormally large number of live bacteria entering the gut, worms were fed bacteria containing a GFP-expressing plasmid (Tan et al., *Proc. Natl. Acad. Sci.* 96: L715-720, 1999). In the case of the wild type N2 strain, 2 hours of feeding on GFP expressing PA14 results in a lumen of a diffuse green color without intact bacteria. After the same period of time, the lumen of the *esp-1* mutant was filled with live, glowing, green bacteria. These results suggest that the ingested bacteria were able to colonize and proliferate in the *esp-1* gut.

Our analysis of *esp-1* further suggests that it represents a previously unidentified feeding defective mutant and that its enhanced susceptibility to PA14 is at least in part a consequence of large numbers of live bacteria entering the gut. The possibility that the *esp-1* mutation has additional effects that favor bacterial colonization and infection has not been ruled out.

#### Characterization of *esp-2* and *esp-8*

The mutant designated *esp-2* was characterized according to standard methods. After backcrossing the *esp-2* mutant, over 70% of *esp-2* young adult animals were dead after only 24 hours on PA14 under SKA conditions (Figure 3). *esp-2* was also found to be sensitive to the gram positive pathogen *Enterococcus faecalis*. In addition, *esp-2* animals are somewhat Egl (egg laying defective). Preliminary experiments have shown that approximately 10% of *esp-2* young adults bag after 24 hours on *E. coli*, and the number of bagging animals was found to increase to approximately 30% after 48 hours. In addition, the number of eggs laid over a 48 hour period at 20°C, by *esp-2* animals that do not bag is reduced as compared to N2. However, the sensitivity of *esp-2* to PA14 is not merely due to the Egl defect because *esp-2* males were also found to be sensitive to PA14. *esp-2* males may be defective in mating; although *esp-2* males can be generated by heat shock, several attempts at establishing a male mating stock have failed.

In order to establish the sensitivity of *esp-2* hermaphrodites to PA14 in the absence of any contribution of the *Egl* defect, double mutants of *esp-2* and *esp-8* with the temperature sensitive sterile *glp-4* mutant were constructed. The *glp-4* mutation alone extended the viability of worms on PA14 ( $LT_{50}=72$  hours). A subset of *glp-4* mutant animals also remained alive for an extended period of time on PA14. This mirrored an overall extension of lifespan in a subpopulation of *glp-4* animals. However, *esp-2; glp-4* and *esp-8; glp-4* hermaphrodites showed enhanced susceptibility to PA14 ( $LT_{50}=30$  hours).

To identify mutants with an enhanced susceptibility to pathogens, mutants with non-specific defects in overall health were identified. As an indication of overall health the lifespan of *esp-2* and *esp-8* animals was determined. Lifespan was assayed on plates containing FUDR, a compound that prevents the generation of progeny. The lifespans of *esp-2* and *esp-8* worms were not significantly different from those of wild-type worms. Furthermore, *esp-2* and *esp-8* worms developed and reached adulthood concomitant with wild-type worms.

#### Bacteria Rapidly Colonize the *esp-2* and *esp-8* Gut

Paralleling the enhanced susceptibility of *esp-2* and *esp-8* mutants to PA14 is a rapid accumulation of PA14 in the intestine of these mutants. *esp-2* and *esp-8* mutants fed GFP labeled PA14 accumulated visible levels of GFP PA14 bacteria in their intestine after 22 hours, when only trace amounts were observed in the gut of wild-type worms. The most anterior portion of the intestine is the first region to show accumulation of GFP PA14. The rapid accumulation of GFP PA14 bacteria within the intestine of *esp-2* and *esp-8* worms was not due to constipation or defects in the ability of the worms to grind food. Both *esp-2* and *esp-8* have normal defecation cycles, are not Eat, and have no observable defect in pharynx action.

#### Mapping of *esp-2* and *esp-8*

For *esp-2* and *esp-8* mutants we have utilized the recently developed mapping strain CB4856 that contains a large number of single nucleotide polymorphisms or SNPs (Wicks et al., *WBG* 16(1): 28; see also [http://genome.wustl.edu/gsc/C\\_elegans/SNP/index.html](http://genome.wustl.edu/gsc/C_elegans/SNP/index.html)). Many snip-SNP markers, that are detected by a restriction digest, have been identified from CB4856. CB4856 has several advantages over RW7000 as a mapping strain, there are more SNP markers than TC1 markers for use in mapping and the SNP markers permit the detection of both the CB4856 and the N2 allele. We crossed CB4856 males to *esp-2* and picked

approximately 1,000 F2 hermaphrodite cross progeny directly to SKA plates. After 24 hours on PA14 SKA plates, over 200 dead animals were singly placed onto *E. coli* plates, with the assumption that these would be *esp-2/esp-2* animals. 130 of the dead animals yielded progeny. The *esp-2/esp-2* plates were allowed to starve, the worms were washed  
 5 from the plate, and DNA was prepared from these worms according to standard methods. All of the original plates were saved, so that it was then possible to verify the Esp phenotype of each F2 picked (this was done for 20% of the strains, all critical recombinants were rigorously tested for their Esp phenotype).

Using the available snip-SNP markers, *esp-2* was mapped to a 0.3 map unit region  
 10 left of center on the X chromosome. There are no other previously identified Esp genes in this interval. The *esp-2* interval was also examined using the available *C. elegans* genetic map and sequence data. Candidate open reading frames within this interval were sequenced, including the *sek-1* open reading frame (ORF) that encodes a homolog of the MKK3/MKK6 type map kinase kinase (MAPKK). A single base pair change, G212R,  
 15 was found within the *sek-1* ORF. Microinjection of a 9.25 kb fragment containing the *sek-1* open reading frame rescued both the Esp and Egl phenotypes of *esp-2*. In addition, a *sek-1* deletion allele that removes kinase domains II-XI of SEK-1 showed enhanced susceptibility to PA14. These results indicate that *esp-2* is *sek-1*. The wild type sequences of the *sek-1* mRNA and SEK-1 amino acid sequences are found in Genbank,  
 20 accession numbers AB060731 and BAB43977, respectively.

Using standard snip-SNP markers, *esp-8* was mapped to a 500 kb region of chromosome II. In addition, the *esp-8* interval was examined using the available *C. elegans* genetic map and sequence data. Within this interval, the SEK-1 activator *nsy-1*, a map kinase kinase kinase (MAPKKK) was identified. Sequencing of the *esp-8* allele  
 25 revealed an early stop codon at position 1013 in *nsy-1*. Microinjection of a genomic fragment containing the *nsy-1* ORF and 3.8 kb of upstream promoter rescued the Esp and Egl phenotypes of *esp-8*. These results indicated that *esp-8* is *nsy-1*. Accordingly, *C. elegans nsy-1* encodes a homologue of the human MAPKKK, ASK1, the apoptosis signal-regulating kinase, an activator of p38 and JNK. The wild type amino acid  
 30 sequence of *esp-8* is shown in Sagasti et al., *Cell* (2001) 105: 221-232 and the genomic sequence is included in cosmid F59A6.1 (GenBank accession number U41994).

#### *nsy-1* and *sek-1* Function in a Map Kinase Signaling Cascade

The *nsy-1* and *sek-1* genes have been shown to function in a map kinase signaling  
 35 cascade that controls a lateral signaling decision in the AWC olfactory neurons. The *nsy-1* gene was isolated in a screen for Neuronal Symmetry mutants. These mutants express

the olfactory receptor, *str-2*, symmetrically in each of the two bilaterally symmetric AWC olfactory neurons, rather than asymmetrically in only one of the two AWC neurons as wild-type worms do. Two alleles of *nsy-1(ky397)* and *nsy-1(ky400)* were identified in a screen for Nsy mutants. These alleles were tested for the Esp phenotype. Both *ky397* and *ky400*, nonsense mutations in *nsy-1*, were sensitive to PA14. In addition, a deletion allele *sek-1(km4)* that removed SEK-I kinase domains II-XI was also tested. The *km4* allele was generated using a standard transposon-based mutagenesis method. Like *nsy-1*, *sek-1(km4)* expressed the *str-2* odor receptor in both AWC neurons and showed enhanced susceptibility to PA14. Based on these data the *nsy-1/sek-1* map kinase signaling cascade was found to play a role in defense against pathogens.

#### NSY-1/SEK-1 Acts Through p38 Map Kinase to Fight Bacterial Infections

The MKK3/MKK6 MAPKKs are specific activators of p38 map kinases in other organisms. *C. elegans* SEK-1 was shown to phosphorylate mammalian p38 *in vitro*. Two p38 map kinases, *pmk-1* and *pmk-2*, were identified in *C. elegans*. *pmk-1* and *pmk-2* are arranged in an operon. A deletion mutant of *pmk-2*, which is the first gene in the operon, was found to be non-viable. No deletion in *pmk-1* is available. To address whether p38 might play a role in the response to pathogens, *pmk-1* gene activity was inhibited by RNAi. Wild-type L1 larval animals were synchronized by hatching overnight in M9, then dropped onto RNAi feeding plates spread with bacteria containing either a *pmk-1* RNAi vector or the RNAi vector without insert. Worms were grown until the L4 stage on the RNAi bacterial lawn and then washed off in M9 and dropped onto PA14. *pmk-1* RNAi resulted in enhanced susceptibility to PA14. At 27 hours after exposure to PA14 only 37% of the *pmk-1* RNAi animals were alive. At 32 hours none of the *pmk-1* RNAi worms was alive, while 80% of the control group were still living. *pmk-1* is found on cosmid B0218.3 (Genbank accession number U58752), and the amino acid sequence of the PMK-1 protein is found in GenBank (accession number AAB00664).

#### UNC-43 CaMKII, An Upstream Activator of *nsy-1* in Signaling Neuronal Fates, Does Not Play a Role in the Response to Pathogens

*C. elegans unc-43* encodes CaMKII. *unc-43* was found to be expressed in many cells that also express *nsy-1*, including neurons, muscle and intestine. *unc-43* loss-of-function (lf) mutants expressed *str-2* in both AWC neurons, as *nsy-1*(lf) mutants did. *unc-43* gain-of-function (gf) mutants had the opposite phenotype, expressing *str-2* in neither AWC. Epistasis analysis indicated that *nsy-1* is genetically downstream of *unc-*

43. In addition, *C. elegans* CaMKII /UNC-43 was found to associate with NSY-1/MAPKKK in heterologous cells. This indicated that UNC-43 activated the NSY-1 signaling cassette to execute a signal required for asymmetric olfactory neuron fate.

To test whether *unc-43* was also required to activate *nsy-1* in response to pathogens, several *unc-43* mutants response to PA14 was tested under slow killing conditions. The *unc-43(lf)* mutants showed no or little enhanced susceptibility to PA14, suggesting that CaMKII does not activate *nsy-1* in response to pathogens. In contrast, *unc-43(gf)* mutants died more rapidly than wild-type worms did when exposed to PA14. This susceptibility was most likely due to the constipation phenotype of *unc-43(gf)*. It was previously observed that mutants defective in the expulsion step of the defecation motor program had an enhanced susceptibility to PA14, presumably due to their reduced ability to clear the pathogenic bacteria from the gut. The observation that *unc-43(lf)* mutants died concomitantly with wild-type worms when exposed to PA14 implies that calcium may not be a primary signal in activation of the *nsy-1* map kinase signaling cassette in response to pathogens and distinguishes the pathogenic signaling pathway from that of neuronal differentiation.

#### Saturation Screen for *C. elegans* Mutants that are Sensitive to Infection Mediated Killing by PA14

Using the above-described methods, a large collection of *C. elegans* mutants having enhanced susceptibility to pathogen infection mediated killing is readily generated. Such mutants are then used to define the molecular pathways and host pathogen defense responses utilized by *C. elegans* to combat infection.

Mutants identified using these screens may then be characterized and categorized as follows. (1) Mutants are tested for growth on *E. coli*, and only mutants showing premature death on PA14, but not on *E. coli* are selected for detailed characterization. (2) Highly penetrant mutants that segregate as a single locus in standard backcrossing experiments are also selected for detailed characterization. (3) Mutants showing either a (i) constipated phenotype on *E. coli*, or (ii) eating defect, particularly a grinding defect, are generally not of immediate interest. The constipated phenotype is easily scored under the dissecting microscope and eating defective mutants generally appear thin and somewhat starved. All eating defective mutants are screened for an aberration in the action of the grinder by observation under Nomarski optics. (4) Additional pathogens that kill *C. elegans* are also useful for analyzing host response, such pathogens include the gram positive *Enterococcus faecalis* and *Salmonella typhimurium*. Mutants showing an enhanced sensitivity to a plurality of pathogens are especially useful, e.g., mutants



having enhanced susceptibility to PA14, *Enterococcus*, and *Salmonella*. To avoid mutants that are merely compromised in their health, mutants that are sensitive to two but not all three pathogens are also useful.

Mutants selected using the above-mentioned guidelines are further analyzed. For example, a mutant may be placed into a class based on the pattern and kinetics of accumulation of PA14 in the gut. This analysis is useful for further characterizing the mutant phenotype; determining whether more live bacteria are entering the gut, and whether the PA14 proliferate more rapidly in a given Esp mutant or to a higher titer. The profile of accumulation of PA14 in the gut is generally examined in two ways. A GFP carrying PA14 strain is used to follow the accumulation of bacteria in the gut of the various *C. elegans* Esp mutants by direct observation under the UV microscope. In addition, the number of live bacteria in the gut is quantitated using pulse/chase experiments involving feeding the *C. elegans* mutants PA14 for a short amount of time, grinding up the worms to recover live bacteria, and counting the bacteria after plating on the appropriate media.

Esp mutants may also be categorized based on their sensitivity to PA14 having mutations in known virulence factors. There are currently 23 PA14 mutants that have been shown to be attenuated in the *C. elegans* slow killing assay and more are continually being identified. To identify *C. elegans* host pathogen defense genes that respond to particular virulence factors or groups of virulence factors, mutant worms are tested against PA14 mutants in known virulence factors whose role in pathogenesis is well defined and conserved across multi-host systems.

Esp mutants may also be classified based on their expression of *C. elegans* pathogen regulated genes. To identify pathogen regulated genes in *C. elegans*, worms exposed to pathogens, and RNA is extracted from the nematodes over the time course of infection. This RNA will be then used to hybridize to DNA microarrays. The expression of genes that are identified as pathogen regulated will be examined in the various mutant backgrounds in order to place the Esp mutants in a regulatory hierarchy.

#### Cloning of *C. elegans* Esp genes

Using the CB4856 mapping strain, map positions for a large number of *C. elegans* Esp mutants are routinely obtained, and such mutants may be mapped using standard techniques to a several map unit interval. Candidate Esp genes for cloning are those that present strong phenotypes and fall into the exemplary classes described above. In order to clone putative Esp genes, it is necessary to obtain a fine map position (on the order of

0.2-0.5 map units), and to obtain informative recombinants to define a small genetic interval. The phenotype of each recombinant (e.g., it has been observed that even for very strong Esp mutants up to 10% of the animals picked in the mapping experiments as esp/esp are in fact either heterozygous or homozygous for the CB4856 chromosome) is carefully verified. Continued mapping with physical markers using CB4856 and classical mapping with applicable visual markers is useful to obtain a fine map position for Esp genes of interest. Once a particular Esp gene is delimited to a small region, cloning is accomplished using a variety of methods such as microinjection rescue with cosmid pools and direct sequencing (Mello et al., *EMBO* 10:3959-3970, 1991). Since many of the Esp mutants have pleiotropic phenotypes, this information is useful for identifying candidate genes corresponding to an Esp genes. Candidate genes are then tested to determine whether they correspond to an Esp gene using such standard methods as microinjection rescue or complementation tests (if mutants already exist in the candidate).

For example, fine mapping, cosmid rescue, and DNA sequencing revealed that the *esp-1* mutation was in the troponin T gene.

#### Alternative Methods to the Identification of Host Defense Genes in *C. elegans*

In addition to the traditional methods of mutagenesis and gene cloning described above, RNA-mediated interference (RNAi) technology (Fire et al., *Nature* 391: 806-811, 1998), in which sequence-specific silencing of genes is accomplished by introduction into the worm of double-stranded RNA (dsRNA), is utilized to identify genes involved in the *C. elegans* response to pathogens. Candidate genes identified through sequence analysis of the *C. elegans* genome are tested for their role in pathogen susceptibility by silencing genes of the nematode using either microinjection of dsRNA or feeding of worms with bacteria that are expressing dsRNA. A synchronized population of L4 N2 (wild-type) nematodes is either microinjected with dsRNA that has been synthesized from an *in vitro* transcription reaction or fed an *E. coli* strain that has been engineered to produce dsRNA. The progeny of the exposed L4 worms are subsequently grown to the L4 stage and assayed for enhanced susceptibility to a pathogen (e.g., *P. aeruginosa* or *E. faecalis*) using the slow-killing protocols described above. The sequence of the dsRNA dictates the specific gene being silenced, and an alteration in the susceptibility of the worm to killing may be attributed to the loss of function of the silenced gene.

Furthermore, genes involved in *C. elegans* host defense are identified using genome-wide screening RNAi methodology (Fraser et al., *Nature* 408: 325-330, 2000; Gonczey et al., *Nature* 408: 331-336, 2000). *C. elegans* worms are injected with dsRNA or fed bacteria expressing dsRNA corresponding to individual genes targeted for gene

silencing, then subjected to exposure to a pathogen. The sequence of the injected or ingested dsRNA effecting increased susceptibility of the nematode to the pathogen provides the identity of the gene that has been affected, indicating a role in the host response.

For example, a library of bacteria engineered to express dsRNA corresponding to individual specific clones (e.g., *C. elegans* genes) is constructed by standard methods. Subsequently, L4 worms are placed on the library of bacteria as a food source. The progeny of these worms are continually grown on the dsRNA-expressing bacteria according to Fraser et al. (*Nature* 408: 325-330, 2000) until the L4 stage, at which point a pathogen is added to the food source, or alternatively, the worms are then transferred to a plate with pathogen for further assay. Performed in a systematic manner, the *C. elegans* genome is screened for all genes that confer increased susceptibility to pathogen when silenced by RNAi.

#### MapK Signaling Cascades and Identification of Innate Immunity Genes in *C. elegans*

As discussed above, the identification of *esp-2*, *esp-8*, and *pmk-1* highlighted the importance of MapK signal transduction in generating a *C. elegans* host defense response. Accordingly, the identification of a MapK signal transduction cascade facilitates the isolation of additional *C. elegans* innate immunity genes encoding components of the MAPK signaling pathway. Genes identified as components of the *C. elegans* MAPK signal cascade may have mammalian homologues that have not yet been identified in the mammalian innate immunity response.

To identify additional *C. elegans* innate immunity genes, the *C. elegans* genome sequence is analysed for additional members of MAPK signaling cascades. Exemplary genes of the MapK signal transduction pathway include MAPKKKs, MAPKKs, and MAPKs. *C. elegans* homologues of p38 (three p38 homologues in *C. elegans*), *jnk-1* map kinases and their upstream activating MAPKK's and MAPKKKs are useful in the methods of the invention. The role of the MAPKKK, MAPKK, or MAPK in innate immunity is then tested using the methods described herein. For example, the MAPK, *jnk-1*, is targeted for deletion or inactivation, for example, by RNAi using standard methods. Deletions are isolated using a PCR-based screen of a chemically mutagenized worm library. The deletion mutants or RNAi containing worms are then characterized for Esp using methods described herein. Worms expressing an attenuated MapK signal transduction pathway that are susceptible to pathogen infection are taken as useful in the invention.

10042066 "101801

In addition, forward genetic screens are performed in sensitized backgrounds to identify additional components of MAPK signaling pathways. *esp-2* worms, for example, are mutagenized according to standard methods and mutant worms are then identified that either suppress or enhance the *esp-2* PA14 sensitivity phenotype. Such mutants are then used to define the MAPK pathways and host pathogen defense responses utilized by *C. elegans* to combat infection. Mutants identified using these screens may then be characterized and categorized as previously described.

#### Compound Screening Assays

As discussed above, our experimental results demonstrated that mutations in host pathogen defense genes, e.g., *esp-1*, *esp-2*, *esp-8*, or *pmk-1* render the nematode, *C. elegans*, more susceptible to pathogen infection. Based on this discovery we have also developed a screening procedure for identifying therapeutic compounds (e.g., drugs) which can be used to promote or enhance the ability of a host to combat pathogen infection, block pathogen virulence, or both. In general, the method involves screening any number of compounds for therapeutically-active agents by employing the pathogen/nematode killing system (e.g., the PA14/*C. elegans* slow killing assay) described herein. Based on our demonstration that mutant *C. elegans* are more susceptible to PA14 and *E. faecalis*, e.g., the Esp mutants described herein, it will be readily understood that a compound which promotes a host's defense response provides an effective therapeutic agent in a mammal (e.g., a human patient). Since the screening procedures of the invention are performed *in vivo*, it is also unlikely that the identified compounds will be highly toxic to the host organism.

In general, the chemical screening methods of the invention provide a straightforward means for selecting natural product extracts or compounds of interest from a large population which are further evaluated and condensed to a few active and selective materials. Constituents of this pool are then purified and evaluated in the methods of the invention to determine their anti-pathogenic activity.

#### Test Extracts and Compounds

In general, novel anti-pathogenic drugs are identified from large libraries of both natural product or synthetic (or semi-synthetic) extracts or chemical libraries according to methods known in the art. The screening method of the present invention is appropriate and useful for testing compounds from a variety of sources for possible anti-pathogenic activity. The initial screens may be performed using a diverse library of compounds, but the method is suitable for a variety of other compounds and compound libraries. Such

compound libraries can be combinatorial libraries, natural product libraries, or other small molecule libraries. In addition, compounds from commercial sources can be tested, as well as commercially available analogs of identified inhibitors.

For example, those skilled in the field of drug discovery and development will understand that the precise source of test extracts or compounds is not critical to the screening procedure(s) of the invention. Accordingly, virtually any number of chemical extracts or compounds can be screened using the methods described herein. Examples of such extracts or compounds include, but are not limited to, plant-, fungal-, prokaryotic- or animal-based extracts, fermentation broths, and synthetic compounds, as well as modification of existing compounds. Numerous methods are also available for generating random or directed synthesis (e.g., semi-synthesis or total synthesis) of any number of chemical compounds, including, but not limited to, saccharide-, lipid-, peptide-, and nucleic acid-based compounds. Synthetic compound libraries are commercially available from Brandon Associates (Merrimack, NH) and Aldrich Chemical (Milwaukee, WI). Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant, and animal extracts are commercially available from a number of sources, including Biotics (Sussex, UK), Xenova (Slough, UK), Harbor Branch Oceanographics Institute (Ft. Pierce, FL), and PharmaMar, U.S.A. (Cambridge, MA). In addition, natural and synthetically produced libraries are produced, if desired, according to methods known in the art, e.g., by standard extraction and fractionation methods. Furthermore, if desired, any library or compound is readily modified using standard chemical, physical, or biochemical methods.

In addition, those skilled in the art of drug discovery and development readily understand that methods for dereplication (e.g., taxonomic dereplication, biological dereplication, and chemical dereplication, or any combination thereof) or the elimination of replicates or repeats of materials already known for their anti-pathogenic activity should be employed whenever possible.

When a crude extract is found to have activity that promotes or enhances a host's defense to a pathogen, further fractionation of the positive lead extract is necessary to isolate chemical constituents responsible for the observed effect. Thus, the goal of the extraction, fractionation, and purification process is the careful characterization and identification of a chemical entity within the crude extract having anti-pathogenic activity. Methods of fractionation and purification of such heterogenous extracts are known in the art. If desired, compounds shown to be useful agents for the promoting or enhancing a host defense response are chemically modified according to methods known in the art.

Since many of the compounds in libraries such as combinatorial and natural products libraries, as well as in natural products preparations, are not characterized, the screening methods of this invention provide novel compounds which are active as inhibitors or inducers in the particular screens, in addition to identifying known compounds which are active in the screens. Therefore, this invention includes such novel compounds, as well as the use of both novel and known compounds in pharmaceutical compositions and methods of treating.

There now follows examples of high-throughput systems useful for evaluating the efficacy of a molecule or compound in promoting or enhancing a host's resistance to a pathogen. These examples are provided to illustrate, not limit, the invention.

#### Exemplary High Throughput Screening Systems

To evaluate the efficacy of a molecule or compound in promoting host resistance to, or inhibiting pathogenicity of a pathogen, a number of high throughput assays may be utilized.

For example, to enable mass screening of large quantities of natural products, extracts, or compounds in an efficient and systematic fashion *Caenorhabditis elegans* (e.g., *esp-1* or *esp-2*, or *esp-8* or strains that include dsRNA, such as *pmk-1*, as described herein) are cultured in wells of a microtiter plate, facilitating the semiautomation of manipulations and full automation of data collection. As is discussed above, bacterial pathogens kill *C. elegans* under slow killing conditions and worms having enhanced susceptibility to such pathogens are readily isolated.

To evaluate the ability of a test compound or extract to promote a host's resistance to a pathogen or to repress pathogenicity of a pathogen, a test compound or extract is inoculated at an appropriate dosage into an appropriate agar medium seeded with an appropriate amount of an overnight culture of a pathogen, e.g., *S. typhimurium* strain LT2 or PA14. If desired, various concentrations of the test compound or extract can be inoculated to assess dosage effect on both the host worm and the pathogen. Worms having enhanced susceptibility to a pathogen are engineered and identified as described herein. Control wells are inoculated with non-mutated worms (negative control) or a mutated worm in the absence of a test compound or extract (positive control) or worms lacking dsRNA. Plates are inoculated with the pathogen and then incubated 24 hours at 37°C to facilitate the growth of the pathogen. Microtiter dishes are subsequently cooled to 25°C, and two *C. elegans* L4 hermaphrodites (either mutant or wild type) expressing a detectable marker such as GFP are added to the plate and incubated at 25°C, the upper limit for normal physiological integrity of *C. elegans*. At an

appropriate time interval, e.g., 24 hours, wells are examined for surviving worms, the presence of progeny, or both, e.g., by visual screening or monitoring motion of worms using a motion detector, or monitoring the fluorescence of the nematodes.

Comparative studies between treated and control worms (or larvae) are used to determine the relative efficacy of the test molecule or compound in promoting the host's resistance to the pathogen or inhibiting the establishment of a persistent infection. A test compound which effectively stimulates, boosts, enhances, increases, or promotes the host's resistance to the pathogen or which inhibits, inactivates, suppresses, represses, or controls pathogenicity of the pathogen, and does not significantly adversely affect the normal physiology, reproduction, or development of the worms is considered useful in the invention.

#### Use

The methods of the invention provide a simple means for identifying host factors and genes that enable a host to combat pathogen infection and compounds capable of either inhibiting pathogenicity or enhancing a host's resistance capabilities to such pathogens. Accordingly, a chemical entity discovered to have medicinal value using the methods described herein are useful as either drugs, or as information for structural modification of existing anti-pathogenic compounds, e.g., by rational drug design.

For therapeutic uses, the compositions or agents identified using the methods disclosed herein may be administered systemically, for example, formulated in a pharmaceutically-acceptable buffer such as physiological saline. Preferable routes of administration include, for example, subcutaneous, intravenous, interperitoneally, intramuscular, or intradermal injections which provide continuous, sustained levels of the drug in the patient. Treatment of human patients or other animals will be carried out using a therapeutically effective amount of an anti-pathogenic agent in a physiologically-acceptable carrier. In the context of treating a bacterial infection a "therapeutically effective amount" or "pharmaceutically effective amount" indicates an amount of an antibacterial agent, e.g., as disclosed for this invention, which has a therapeutic effect. This generally refers to the inhibition, to some extent, of the normal cellular functioning of bacterial cells causing or contributing to a bacterial infection. The dose of antibacterial agent which is useful as a treatment is a "therapeutically effective amount." Thus, as used herein, a therapeutically effective amount means an amount of an antibacterial agent which produces the desired therapeutic effect as judged by clinical trial results, standard animal models of infection, or both. This amount can be routinely determined by one skilled in the art and will vary depending upon several factors, such as the particular

bacterial strain involved and the particular antibacterial agent used. This amount can further depend on the patient's height, weight, sex, age, and renal and liver function or other medical history. For these purposes, a therapeutic effect is one which relieves to some extent one or more of the symptoms of the infection and includes curing an infection.

The compositions containing antibacterial agents of virulence factors or genes can be administered for prophylactic or therapeutic treatments, or both. In therapeutic applications, the compositions are administered to a patient already suffering from an infection from bacteria (similarly for infections by other microbes), in an amount sufficient to cure or at least partially arrest the symptoms of the infection. An amount adequate to accomplish this is defined as "therapeutically effective amount." Amounts effective for this use will depend on the severity and course of the infection, previous therapy, the patient's health status and response to the drugs, and the judgment of the treating physician. In prophylactic applications, compositions containing the compounds of the invention are administered to a patient susceptible to, or otherwise at risk of, a particular infection. Such an amount is defined to be a "prophylactically effective amount." In this use, the precise amounts again depend on the patient's state of health, weight, and the like. However, generally, a suitable effective dose will be in the range of 0.1 to 10000 milligrams (mg) per recipient per day, preferably in the range of 10-5000 mg per day. The desired dosage is preferably presented in one, two, three, four, or more subdoses administered at appropriate intervals throughout the day. These subdoses can be administered as unit dosage forms, for example, containing 5 to 1000 mg, preferably 10 to 100 mg of active ingredient per unit dosage form. Preferably, the compounds of the invention will be administered in amounts of between about 2.0 mg/kg to 25 mg/kg of patient body weight, between about one to four times per day.

Suitable carriers and their formulation are described, for example, in Remington's *Pharmaceutical Sciences* by E.W. Martin. The amount of the anti-pathogenic agent to be administered varies depending upon the manner of administration, the age and body weight of the patient, and with the type of disease and extensiveness of the disease.

Generally, amounts will be in the range of those used for other agents used in the treatment of other microbial diseases, although in certain instances lower amounts will be needed because of the increased specificity of the compound. A compound is administered at a dosage that inhibits microbial proliferation.

All publications and patents mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent was specifically and individually indicated to be incorporated by reference.



From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, can make various changes and modifications of the invention to adapt it to various usages and conditions. Thus, other embodiments are also within the claims.

5

What is claimed is:

10042056-101301